Developer docs
API playgroundTry for free, no card

Search company profiles

Tune Therapeutics

Full company profile

uuid00007rb

Namestring
Tune Therapeutics
Legal namestring
Tune Therapeutics, Inc.
Websiteurl
tunetx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Tune Therapeutics is a clinical-stage biotechnology company developing a proprietary epigenetic programming platform called TEMPO for the treatment of disease. Founded in December 2021, the company uses a "genetic tuning" modality to modulate gene expression by adding or removing epigenetic marks — including DNA methylation, demethylation, and histone modification — without cutting or altering DNA sequences. The modular TEMPO architecture pairs a catalytically inactive DNA-binding domain (compatible with dCas9, ZFP, or TALE scaffolds) with interchangeable effector proteins, enabling graded, tunable, and reversible control of gene activity, durable changes from a single transient delivery, and simultaneous multiplex targeting of multiple genes. The platform's lead clinical candidate, TUNE-401, is a first-in-class LNP-RNA epigenetic silencer for chronic Hepatitis B that directly methylates both cccDNA and integrated HBV DNA; it is currently in Phase 1b/2a trials in New Zealand, Hong Kong, and Moldova, with positive proof-of-concept data presented at EASL 2026 showing 100% biomarker repression at higher dose levels and durability out to 17 months from a single dose. The pipeline also includes a preclinical PCSK9 epi-repressor for cardiovascular disease and a CAR T-cell engineering program for solid tumor immuno-oncology.

The company operates a platform-plus-pipeline business model with no current product revenue, pursuing a partnership-driven go-to-market motion that targets large pharmaceutical collaborators and out-licensing opportunities. It employs 51-100 staff across Durham, NC and Seattle, WA, and uses a network of leading academic KOLs and major hepatology/gene therapy conferences (EASL, AASLD, ASGCT, HepDART) for scientific disclosure. Future revenue is expected to derive from out-licensing deals, pharma co-development arrangements, and ultimately approved therapeutic sales. Tune has raised approximately $215M in venture capital across two rounds — a $40M Series A in December 2021 co-led by NEA and Emerson Collective, and a $175M+ Series B in January 2025 co-led by NEA, Yosemite, Regeneron Ventures, and Hevolution Foundation. The company's foundational IP was licensed from Duke University, based on the research of scientific co-founders Charles Gersbach (Duke) and Fyodor Urnov (UC Berkeley/IGI), who are pioneers in the genome and epigenome editing field. The leadership team includes CEO and Chairman John McHutchison (former Gilead CSO and Assembly Biosciences CEO), CSO Derek Jantz (former Precision BioSciences CSO and co-founder), and President/CFO/COO Akira Matsuno (former CFO of Lyell Immunopharma and VP at Juno Therapeutics).

Short descriptiontext

Tune Therapeutics is a clinical-stage biotechnology company developing TEMPO, a proprietary epigenome editing platform that modulates gene expression without cutting DNA. Its lead candidate, TUNE-401, is an LNP-RNA epigenetic silencer in Phase 1b/2a trials for chronic Hepatitis B.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenome editing therapeutics, gene therapy platform, hepatitis B treatment, epigenetic gene silencing, cell therapy engineering
Industry2 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Epigenetic Editing Therapeutics / Gene Therapy
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue clinical-stage development
TypeLicensing Royalties
Description

Tune Therapeutics is currently a clinical-stage biotechnology company with no commercial product revenue. The company is investing venture capital into the development of TUNE-401 (HBV) and other pipeline programs, with future revenue expected from potential pharma licensing deals, partnerships, and ultimately approved therapeutic sales. Partnering inquiries are directed via partners@tunetx.com.

tunetx.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Not applicable — pre-revenue clinical-stage biotech
ModelOtherBilling cadenceMulti-year contract
Notes

No pricing publicly disclosed. Future pricing (if approved) is expected to follow specialty biologic / gene therapy pricing models typical of innovative curative therapies, but no specifics are available.

tunetx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1TEMPO
Description

Tune's proprietary 'genetic tuning' epigenome editing platform — a modular system combining a DNA-binding domain with epigenetic effector domains to activate, silence, or fine-tune gene expression without cutting DNA.

tunetx.com
Core offering1 text field

Tune Therapeutics develops and sells investigational epigenetic editing therapeutics built on its proprietary TEMPO platform, which modulates gene expression up or down without cutting DNA. Its lead clinical-stage candidate TUNE-401 is an LNP-RNA-delivered epigenetic silencer for chronic Hepatitis B currently in Phase 1b/2a trials, with a preclinical PCSK9 epi-repressor program for cardiovascular disease and exploratory applications in CAR-T cell engineering and regenerative medicine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 100% biomarker repression at higher dose levels in Phase 1b/2a HBV trial
+5 more records
Product overview1 text field

Tune Therapeutics operates a platform-plus-pipeline architecture centered on its proprietary TEMPO genetic tuning platform. TEMPO is the core engine: a modular system that combines a catalytically dead DNA-Binding Domain (e.g., dCas9, ZFP, or TALE) with interchangeable epigenetic effector domains to activate, silence, or fine-tune genes without cutting DNA. Built on top of TEMPO are multiple therapeutic programs, most notably the lead clinical-stage candidate TUNE-401 (an LNP-RNA epigenetic silencer for chronic Hepatitis B, currently in Phase 1b/2a development) and a preclinical PCSK9 epi-repressor program for cardiovascular disease demonstrated in non-human primates. The platform is also being applied to enhance cell therapies (including CAR T cells for solid tumors) and to enable regenerative medicine applications. Together, the TEMPO platform and its derivative programs position Tune to address common, chronic, and age-related diseases that are beyond the reach of conventional gene editing.

Product and service3 records
1TEMPO Platform
CategoryCore Platform
Description

Tune Therapeutics' proprietary genetic tuning platform. TEMPO is a modular system with two switchable elements: a DNA-Binding Domain (DBD) that binds to a tightly-targeted region of the genome without cutting DNA, and interchangeable effectors that alter local epigenetic marks or recruit proteins to alter the packaging and accessibility of a gene. It enables graded, tunable, and reversible control over gene activity for activating, silencing, and fine-tuning the output of specific genes to reverse cellular dysfunction and disease.

2TUNE-401
CategoryLead Therapeutic Candidate
Description

First-in-class investigational epigenetic silencing therapy for the treatment of chronic Hepatitis B (HBV) infection. TUNE-401 is an intravenously delivered LNP-RNA epigenetic silencing therapy translated in the liver into an HBV-targeting protein that potently and selectively methylates both cccDNA and integrated HBV DNA. It is the first epigenetic therapy to enter clinical trials for an infectious disease and the first treatment to aim to silence both integrated HBV and HBV cccDNA at the epigenetic level without cutting or editing DNA. Lipid nanoparticle technology is licensed from Acuitas Therapeutics Inc. Currently advancing into a larger Phase 2 study expected to initiate as early as late 2026.

3PCSK9 Epi-Repressor Program
CategoryPreclinical Therapeutic Program
Description

A TEMPO epi-repressor targeting the PCSK9 gene, encoded into RNA and delivered to cells via lipid nanoparticle (LNP). Preclinical proof-of-concept demonstrated stable repression of PCSK9 (ongoing past four months) and ~56% reduction in LDL-cholesterol levels in non-human primates following a single treatment, with methylation patterns practically unchanged between day 7 and day 85. Repression of up to 98% with effects maintained for over 6 months in rapidly dividing liver cells. Validated epigenetic DNA methylation as the core mode of action for cardiovascular disease applications.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-07
Description

Professor Man-Fung Yuen (Chair Professor of The University of Hong Kong and Chief of the Division of Gastroenterology and Hepatology at Queen Mary Hospital) leads the TUNE-401 clinical trial at the Hong Kong site following Certificate for Clinical Trial approval from the Hong Kong Department of Health.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-14
Description

Acuitas Therapeutics provides the lipid nanoparticle (LNP) technology used in TUNE-401 to deliver RNA encoding the HBV-targeting epi-silencing protein to liver cells. Acuitas LNP technology is foundational to Tune's clinical HBV program.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-11-14
Description

Dr. Ed Gane (Professor of Medicine, University of Auckland; Chief Hepatologist and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital) serves as Lead Investigator for the TUNE-401 Phase 1b/2a clinical trial at the Auckland, New Zealand site. Dr. Gane also presented the EASL 2026 oral data readout.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-12-02
Description

Tune Therapeutics secured foundational intellectual property from Duke University at its founding, based on decades of epigenome editing research by co-founder Charles Gersbach (John W. Strohbehn Distinguished Professor of Biomedical Engineering at Duke and Director of the Duke Center for Advanced Genomic Technologies).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage infectious disease company with multiple HBV programs (siRNA, neutralizing antibodies, capsid inhibitors) pursuing functional cure. Comparable as a major competing player in the chronic HBV curative space.

TypeBroad incumbent
Description

Clinical-stage RNA interference (RNAi) therapeutics company with a deep HBV pipeline using LNP delivery to the liver. Direct overlap with Tune's TUNE-401 in both indication (HBV) and delivery modality (LNP to hepatocytes).

TypeDirect peer
Description

Clinical-stage epigenetic editing company developing single-dose therapies that target chromatin regulators to silence or activate genes. Directly comparable to Tune as a fellow epigenome editing platform company pursuing similar indications and partnering-led business model.

TypeDirect peer
Description

Clinical-stage epigenomic programming company using engineered omega-Insulated Genomic Domains to modulate gene expression. Comparable to Tune in modality (epigenomic control of single or multiple genes) and stage (clinical-stage with platform-plus-pipeline structure).

TypeEmerging player
Description

Earlier-stage company applying CRISPR-based epigenetic editing to neurological and metabolic diseases. Comparable modality (gene regulation without DNA cleavage) with narrower indication focus than Tune.

TypeBroad incumbent
Description

Clinical-stage base editing company with strong liver-directed (LNP-delivered) programs including a PCSK9 cardiovascular program that directly overlaps Tune's preclinical PCSK9 epi-repressor. Comparable delivery modality and indication overlap.

TypeBroad incumbent
Description

Clinical-stage in vivo CRISPR/Cas9 gene editing company co-developing with Regeneron. Tunable in vivo gene modulation via LNP delivery is highly comparable to Tune's TEMPO; co-listed with Tune on Idea Pharma's Disruptive Pioneers 2026.

TypeDirect peer
Description

Clinical-stage cardiovascular gene editing company with lead in vivo PCSK9 program for LDL-C lowering via LNP delivery. Most direct competitor to Tune's PCSK9 epi-repressor program on both modality and indication.

TypeBroad incumbent
Description

Pioneer in zinc finger protein-based gene regulation, including epigenetic approaches, with clinical-stage programs across multiple indications. Directly relevant as a foundational technology comparator (ZFP scaffolds are part of TEMPO's DBD toolkit).

TypeBroad incumbent
Description

Clinical-stage Cas9-based gene editing company with broad pipeline across hemoglobinopathies, oncology and regenerative medicine. Comparable as a large, well-capitalized genetic medicine platform; NEA partner Ali Behbahani has served on both boards.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tune Therapeutics

Epigenetic Editing Therapeutics / Gene Therapytunetx.com

Tune Therapeutics is a clinical-stage biotechnology company developing TEMPO, a proprietary epigenome editing platform that modulates gene expression without cutting DNA. Its lead candidate, TUNE-401, is an LNP-RNA epigenetic silencer in Phase 1b/2a trials for chronic Hepatitis B.

What Tune Therapeutics does

Tune Therapeutics is a clinical-stage biotechnology company developing a proprietary epigenetic programming platform called TEMPO for the treatment of disease. Founded in December 2021, the company uses a "genetic tuning" modality to modulate gene expression by adding or removing epigenetic marks — including DNA methylation, demethylation, and histone modification — without cutting or altering DNA sequences. The modular TEMPO architecture pairs a catalytically inactive DNA-binding domain (compatible with dCas9, ZFP, or TALE scaffolds) with interchangeable effector proteins, enabling graded, tunable, and reversible control of gene activity, durable changes from a single transient delivery, and simultaneous multiplex targeting of multiple genes. The platform's lead clinical candidate, TUNE-401, is a first-in-class LNP-RNA epigenetic silencer for chronic Hepatitis B that directly methylates both cccDNA and integrated HBV DNA; it is currently in Phase 1b/2a trials in New Zealand, Hong Kong, and Moldova, with positive proof-of-concept data presented at EASL 2026 showing 100% biomarker repression at higher dose levels and durability out to 17 months from a single dose. The pipeline also includes a preclinical PCSK9 epi-repressor for cardiovascular disease and a CAR T-cell engineering program for solid tumor immuno-oncology.

The company operates a platform-plus-pipeline business model with no current product revenue, pursuing a partnership-driven go-to-market motion that targets large pharmaceutical collaborators and out-licensing opportunities. It employs 51-100 staff across Durham, NC and Seattle, WA, and uses a network of leading academic KOLs and major hepatology/gene therapy conferences (EASL, AASLD, ASGCT, HepDART) for scientific disclosure. Future revenue is expected to derive from out-licensing deals, pharma co-development arrangements, and ultimately approved therapeutic sales. Tune has raised approximately $215M in venture capital across two rounds — a $40M Series A in December 2021 co-led by NEA and Emerson Collective, and a $175M+ Series B in January 2025 co-led by NEA, Yosemite, Regeneron Ventures, and Hevolution Foundation. The company's foundational IP was licensed from Duke University, based on the research of scientific co-founders Charles Gersbach (Duke) and Fyodor Urnov (UC Berkeley/IGI), who are pioneers in the genome and epigenome editing field. The leadership team includes CEO and Chairman John McHutchison (former Gilead CSO and Assembly Biosciences CEO), CSO Derek Jantz (former Precision BioSciences CSO and co-founder), and President/CFO/COO Akira Matsuno (former CFO of Lyell Immunopharma and VP at Juno Therapeutics).

Tune Therapeutics firmographics

Firmographics
Name
Tune Therapeutics
Legal name
Tune Therapeutics, Inc.
Website
https://tunetx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Tune Therapeutics is a clinical-stage biotechnology company developing TEMPO, a proprietary epigenome editing platform that modulates gene expression without cutting DNA. Its lead candidate, TUNE-401, is an LNP-RNA epigenetic silencer in Phase 1b/2a trials for chronic Hepatitis B.
Ownership category
akta.pro rank

Tune Therapeutics industry classification

Industry
Product category
Epigenetic Editing Therapeutics / Gene Therapy
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Epigenome editing therapeutics
  • Gene therapy platform
  • Hepatitis B treatment
  • Epigenetic gene silencing
  • Cell therapy engineering

Where Tune Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Tune Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pre-revenue clinical-stage development: Tune Therapeutics is currently a clinical-stage biotechnology company with no commercial product revenue. The company is investing venture capital into the development of TUNE-401 (HBV) and other pipeline programs, with future revenue expected from potential pharma licensing deals, partnerships, and ultimately approved therapeutic sales. Partnering inquiries are directed via partners@tunetx.com.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNot applicable — pre-revenue clinical-stage biotech

Go-to-market motion3 records

Distribution channels2 records

Marketing channels8 records

Tune Therapeutics product offering

Product offering

Core offering

Tune Therapeutics develops and sells investigational epigenetic editing therapeutics built on its proprietary TEMPO platform, which modulates gene expression up or down without cutting DNA. Its lead clinical-stage candidate TUNE-401 is an LNP-RNA-delivered epigenetic silencer for chronic Hepatitis B currently in Phase 1b/2a trials, with a preclinical PCSK9 epi-repressor program for cardiovascular disease and exploratory applications in CAR-T cell engineering and regenerative medicine.

Product overview

Tune Therapeutics operates a platform-plus-pipeline architecture centered on its proprietary TEMPO genetic tuning platform. TEMPO is the core engine: a modular system that combines a catalytically dead DNA-Binding Domain (e.g., dCas9, ZFP, or TALE) with interchangeable epigenetic effector domains to activate, silence, or fine-tune genes without cutting DNA. Built on top of TEMPO are multiple therapeutic programs, most notably the lead clinical-stage candidate TUNE-401 (an LNP-RNA epigenetic silencer for chronic Hepatitis B, currently in Phase 1b/2a development) and a preclinical PCSK9 epi-repressor program for cardiovascular disease demonstrated in non-human primates. The platform is also being applied to enhance cell therapies (including CAR T cells for solid tumors) and to enable regenerative medicine applications. Together, the TEMPO platform and its derivative programs position Tune to address common, chronic, and age-related diseases that are beyond the reach of conventional gene editing.

Differentiator

Problem solved

Functional benefit

Brands

  • TEMPO: Tune's proprietary 'genetic tuning' epigenome editing platform — a modular system combining a DNA-binding domain with epigenetic effector domains to activate, silence, or fine-tune gene expression without cutting DNA.

Products and services

  • TEMPO Platform Tune Therapeutics' proprietary genetic tuning platform. TEMPO is a modular system with two switchable elements: a DNA-Binding Domain (DBD) that binds to a tightly-targeted region of the genome without cutting DNA, and interchangeable effectors that alter local epigenetic marks or recruit proteins to alter the packaging and accessibility of a gene. It enables graded, tunable, and reversible control over gene activity for activating, silencing, and fine-tuning the output of specific genes to reverse cellular dysfunction and disease.
  • TUNE-401 First-in-class investigational epigenetic silencing therapy for the treatment of chronic Hepatitis B (HBV) infection. TUNE-401 is an intravenously delivered LNP-RNA epigenetic silencing therapy translated in the liver into an HBV-targeting protein that potently and selectively methylates both cccDNA and integrated HBV DNA. It is the first epigenetic therapy to enter clinical trials for an infectious disease and the first treatment to aim to silence both integrated HBV and HBV cccDNA at the epigenetic level without cutting or editing DNA. Lipid nanoparticle technology is licensed from Acuitas Therapeutics Inc. Currently advancing into a larger Phase 2 study expected to initiate as early as late 2026.
  • PCSK9 Epi-Repressor Program A TEMPO epi-repressor targeting the PCSK9 gene, encoded into RNA and delivered to cells via lipid nanoparticle (LNP). Preclinical proof-of-concept demonstrated stable repression of PCSK9 (ongoing past four months) and ~56% reduction in LDL-cholesterol levels in non-human primates following a single treatment, with methylation patterns practically unchanged between day 7 and day 85. Repression of up to 98% with effects maintained for over 6 months in rapidly dividing liver cells. Validated epigenetic DNA methylation as the core mode of action for cardiovascular disease applications.

Quantifiable outcome

  • 100% biomarker repression at higher dose levels in Phase 1b/2a HBV trial
  • +5 more outcomes

Companies that use Tune Therapeutics

Customer profile

Segments5 records

Ideal customer profiles2 records

Tune Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Tune Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • University of Hong Kong / Queen Mary Hospital (Dr. Man-Fung Yuen)coreImplementation/ SI/ Consulting Partner · 7 January 2025Professor Man-Fung Yuen (Chair Professor of The University of Hong Kong and Chief of the Division of Gastroenterology and Hepatology at Queen Mary Hospital) leads the TUNE-401 clinical trial at the Hong Kong site following Certificate for Clinical Trial approval from the Hong Kong Department of Health.
  • Acuitas Therapeutics Inc.coreTechnology or Integration · 14 November 2024Acuitas Therapeutics provides the lipid nanoparticle (LNP) technology used in TUNE-401 to deliver RNA encoding the HBV-targeting epi-silencing protein to liver cells. Acuitas LNP technology is foundational to Tune's clinical HBV program.
  • University of Auckland / Auckland City Hospital (Dr. Ed Gane)coreImplementation/ SI/ Consulting Partner · 14 November 2024Dr. Ed Gane (Professor of Medicine, University of Auckland; Chief Hepatologist and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital) serves as Lead Investigator for the TUNE-401 Phase 1b/2a clinical trial at the Auckland, New Zealand site. Dr. Gane also presented the EASL 2026 oral data readout.
  • Duke UniversityflagshipOEM/ Whitelabel/ Licensing Partner · 2 December 2021Tune Therapeutics secured foundational intellectual property from Duke University at its founding, based on decades of epigenome editing research by co-founder Charles Gersbach (John W. Strohbehn Distinguished Professor of Biomedical Engineering at Duke and Director of the Duke Center for Advanced Genomic Technologies).

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Tune Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Vir Biotechnology: Clinical-stage infectious disease company with multiple HBV programs (siRNA, neutralizing antibodies, capsid inhibitors) pursuing functional cure. Comparable as a major competing player in the chronic HBV curative space.
  • Arrowhead Pharmaceuticals: Clinical-stage RNA interference (RNAi) therapeutics company with a deep HBV pipeline using LNP delivery to the liver. Direct overlap with Tune's TUNE-401 in both indication (HBV) and delivery modality (LNP to hepatocytes).
  • Beam Therapeutics: Clinical-stage base editing company with strong liver-directed (LNP-delivered) programs including a PCSK9 cardiovascular program that directly overlaps Tune's preclinical PCSK9 epi-repressor. Comparable delivery modality and indication overlap.
  • Intellia Therapeutics: Clinical-stage in vivo CRISPR/Cas9 gene editing company co-developing with Regeneron. Tunable in vivo gene modulation via LNP delivery is highly comparable to Tune's TEMPO; co-listed with Tune on Idea Pharma's Disruptive Pioneers 2026.
  • Sangamo Therapeutics: Pioneer in zinc finger protein-based gene regulation, including epigenetic approaches, with clinical-stage programs across multiple indications. Directly relevant as a foundational technology comparator (ZFP scaffolds are part of TEMPO's DBD toolkit).
  • CRISPR Therapeutics: Clinical-stage Cas9-based gene editing company with broad pipeline across hemoglobinopathies, oncology and regenerative medicine. Comparable as a large, well-capitalized genetic medicine platform; NEA partner Ali Behbahani has served on both boards.

Direct peers

  • Chroma Medicine: Clinical-stage epigenetic editing company developing single-dose therapies that target chromatin regulators to silence or activate genes. Directly comparable to Tune as a fellow epigenome editing platform company pursuing similar indications and partnering-led business model.
  • Omega Therapeutics: Clinical-stage epigenomic programming company using engineered omega-Insulated Genomic Domains to modulate gene expression. Comparable to Tune in modality (epigenomic control of single or multiple genes) and stage (clinical-stage with platform-plus-pipeline structure).
  • Verve Therapeutics: Clinical-stage cardiovascular gene editing company with lead in vivo PCSK9 program for LDL-C lowering via LNP delivery. Most direct competitor to Tune's PCSK9 epi-repressor program on both modality and indication.

Emerging players

  • Epicrispr Biotechnologies: Earlier-stage company applying CRISPR-based epigenetic editing to neurological and metabolic diseases. Comparable modality (gene regulation without DNA cleavage) with narrower indication focus than Tune.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Tune Therapeutics social profiles

Digital presence

Tune Therapeutics compliance and trust

Trust signal

Compliance1 record

Tune Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tune Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Tune Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tune Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tune Therapeutics

What does Tune Therapeutics do?

Tune Therapeutics develops and sells investigational epigenetic editing therapeutics built on its proprietary TEMPO platform, which modulates gene expression up or down without cutting DNA. Its lead clinical-stage candidate TUNE-401 is an LNP-RNA-delivered epigenetic silencer for chronic Hepatitis B currently in Phase 1b/2a trials, with a preclinical PCSK9 epi-repressor program for cardiovascular disease and exploratory applications in CAR-T cell engineering and regenerative medicine.

Is Tune Therapeutics a public or private company?

Tune Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tune Therapeutics founded?

Tune Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is Tune Therapeutics based?

Tune Therapeutics is headquartered in Seattle, United States, in the North America region.

How does Tune Therapeutics make money?

One revenue line is on record: pre-revenue clinical-stage development.

Who are Tune Therapeutics's main competitors?

Broad incumbents on record are Vir Biotechnology, Arrowhead Pharmaceuticals, Beam Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and CRISPR Therapeutics. Direct peers are Chroma Medicine, Omega Therapeutics and Verve Therapeutics. Epicrispr Biotechnologies is listed as an emerging player.

Does Tune Therapeutics have an API?

No public API is recorded for Tune Therapeutics.

What industry is Tune Therapeutics in?

Tune Therapeutics's product category is Epigenetic Editing Therapeutics / Gene Therapy. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 5417 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WowtaleEpigenetic editing with Epicrisper, $90 million Series C funding raisedEpicrispr has raised $90 million in an oversubscribed Series C funding round, distinguishing itself as the only company in epigenetic editing to demonstrate disease control signals in patients. This financial milestone contrasts with competitors like Tune Therapeutics and nChroma Bio, which have secured significant capital but lack comparable clinical proof-of-concept data.NatureEpigenetic editing makes its markMore than a dozen companies are now exploring epigenetic-editing technology, with early-stage clinical trials under way for applications ranging from hepatitis B treatment to cholesterol reduction. Researchers at nChroma Bio demonstrated that a single epigenetic treatment in mice reduced PCSK9 protein levels by over 98% for at least a year, while cynomolgus monkeys showed approximately 90% PCSK9 reduction and 70% LDL cholesterol reduction. Tune Therapeutics reported at the European Association for the Study of the Liver conference that higher doses of their hepatitis B epigenomic treatment eliminated viral protein and RNA biomarkers for up to 17 months in an early-stage trial.NatureCRISPR’s next act: the companies editing the epigenome to treat diseaseEpicrispr Biotechnologies, a South San Francisco start-up, presented data from one of the first epigenetic-editing clinical trials at the International Research Congress on FSHD in late June in Chicago, Illinois, representing a new approach that modifies chemical markers on DNA rather than cutting the genetic code itself. Several companies including Epicrispr, Tune Therapeutics, and nChroma are racing to develop targeted epigenetic editing therapies for conditions including facioscapulohumeral muscular dystrophy (FSHD), hepatitis B, and high cholesterol, with nChroma reporting that a single injection lowered 'bad' cholesterol in monkeys by around 70%. Researchers claim epigenetic editing could be safer than conventional CRISPR because it avoids making cuts in DNA that can disrupt or damage genes, though bioethicists caution that the potency of epigenetic forces warrants careful monitoring.BioWorldEASL spotlight: TUNE-401 advances epigenetic silencing in HBVTune Therapeutics is investigating TUNE-401 as a potential treatment for hepatitis B, with presentations at EASL highlighting the therapy's novelty. The company's work signals a step forward in epigenetic silencing for HBV.BioSpaceTune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026Tune Therapeutics presented Phase 1b/2a data on TUNE-401 at EASL 2026, showing direct epigenetic silencing of HBV cccDNA. The therapy achieved 100% biomarker repression at dose levels 2-4, with pgRNA loss in 4 of 7 HBeAg-negative participants. The company plans a larger Phase 2 trial starting late 2026.Business Wire BlogTune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026Tune Therapeutics presented positive Phase 1b/2a clinical data for TUNE-401, a first-in-class epigenetic silencing therapy for chronic hepatitis B, at the EASL 2026 Congress in Barcelona, demonstrating the first clinical evidence that direct epigenetic silencing of HBV cccDNA can achieve durable antiviral activity. The trial showed 100% biomarker repression at higher dose levels in participants across study sites in New Zealand, Hong Kong, and Moldova, with durability observed out to 17 months and a favorable safety profile. The company is advancing TUNE-401 into a larger Phase 2 study expected to initiate as early as late 2026, with the goal of delivering the first epigenetic backbone therapy for HBV infection affecting over 240 million people globally.PharmaVoiceWho’s winning pharma’s innovation race? The rankings are out.Idea Pharma released its annual Global Innovation and Invention indexes, ranking pharmaceutical companies on their ability to launch new drugs and develop new ones, with Eli Lilly becoming the first company to achieve the No. 1 position on both lists, driven by 45% revenue growth fueled by its weight loss drugs and $202 million acquisition of Engage Biologics. Several major pharma companies saw notable shifts in rankings, with Sanofi rising 19 places to No. 3 and GSK leaping 10 spots to No. 4, while Novo Nordisk fell out of the top 10 and both Pfizer and Bristol Myers Squibb continued to decline due to post-COVID challenges and clinical setbacks. Idea Pharma also introduced its first "Disruptive Pioneers" list highlighting 10 emerging biotechs with cutting-edge technologies, including Revolution Medicines, Parabilis Medicines, Intellia Therapeutics, Tune Therapeutics, and Compass Pathways, which are being developed with early commercialization strategies.Longevity.TechnologyNovel epigenetic silencer shows potential as finite therapy for chronic hepatitis BTune Therapeutics will present Phase 1b/2a data for TUNE-401 at EASL 2026, showing epigenetic silencing of hepatitis B cccDNA. The company says the data provide first clinical evidence of this silencing and deep, durable antiviral activity. The approach is framed as a potential finite therapy for chronic hepatitis B.BioSpaceTune Therapeutics Announces Late-Breaking Oral Presentation for TUNE-401 at European Association for the Study of the Liver Congress 2026Tune Therapeutics will present late-breaking Phase 1b/2a data for TUNE-401 at EASL 2026, highlighting first clinical evidence of epigenetic silencing in chronic hepatitis B. The oral presentation, led by Dr. Ed Gane, aims to demonstrate deep and durable antiviral activity. The congress takes place May 27–30, 2026, in Barcelona.Business Wire BlogTune Therapeutics Announces Late-Breaking Oral Presentation for TUNE-401 at European Association for the Study of the Liver Congress 2026Tune Therapeutics will present late-breaking Phase 1b/2a data for TUNE-401 at EASL 2026 in Barcelona, May 27-30. The epigenetic silencer aims to silence HBV cccDNA, with Dr. Ed Gane presenting the results. The company highlights the potential for a finite therapy.